HK Stock Market Move | HAIXI PHARMA (02637) rose more than 6% in the morning, with HXP056's clinical progress going smoothly and expected to fill the global oral treatment gap in the market for eye diseases.

HAIXI PHARMA (02637) rose more than 6% in the morning, up 5.25% to 198.6 Hong Kong dollars as of press time, with a turnover of 71.3213 million Hong Kong dollars. On the news front, HAIXI PHARMA previously announced the latest progress of the new generation original innovative drug project HXP056 for the oral treatment of retinal diseases. Previous studies have confirmed that the drug is well-tolerated, with stable and controllable pharmacokinetic (PK) data, excellent dose-related systemic exposure, and preliminary positive therapeutic effects. While advancing phase I studies, the company has initiated phase II expanded clinical research enrollment in the fourth quarter of 2025, accelerating progress and laying a solid foundation for subsequent phase III research and optimal dosage assessment, steadily moving towards the goal of the world's first oral drug for the treatment of retinal diseases. Huayuan Securities pointed out that the retinal disease market is growing, and there are pain points in existing therapies. HAIXI PHARMA is focusing on the oral small molecule drug HXP056 for retinal diseases, intending to cover indications such as wAMD, DME, and RVO. Preclinical studies have shown that it can penetrate the blood-retina barrier and achieve high distribution in the eye with low systemic exposure. Clinical phase I trials began in June 2025, showing the potential to reshape the treatment experience for retinal diseases from the administration method.